How have ENGNW shares performed in 2024?

enGene's stock was trading at $0.85 at the beginning of the year. Since then, ENGNW stock has increased by 384.7% and is now trading at $4.12. View the best growth stocks for 2024 here .

Are investors shorting enGene?

enGene saw a drop in short interest during the month of April. As of April 15th, there was short interest totaling 1,700 shares, a drop of 76.4% from the March 31st total of 7,200 shares. Based on an average daily trading volume, of 40,600 shares, the short-interest ratio is presently 0.0 days. View enGene's Short Interest .

Is enGene a good dividend stock?

enGene (NASDAQ:ENGNW) pays an annual dividend of $1.58 per share and currently has a dividend yield of 0.00%.

How do I buy shares of enGene?

Shares of ENGNW stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here .

NASDAQ:ENGNW

enGene (ENGNW) Stock Price, News & Analysis

→ The asset beating inflation by 4x (From Colonial Metals) (Ad)

Free ENGNW Stock Alerts

$4.12

-0.18 (-4.19%)

(As of 05/3/2024 ET)

Compare

Today's Range: $4.12
▼
$4.70
50-Day Range: $3.52
▼
$6.38
52-Week Range: $0.39
▼
$6.50

Volume: 3,525 shs
Average Volume: 36,669 shs
Market Capitalization: N/A

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: N/A

Stock Analysis Chart Competitors Financials SEC Filings Short Interest Social Media

Get enGene alerts:

Ad Colonial Metals

The asset beating inflation by 4x

"Trump Loophole" Beats Inflation? Inflation has been out of control for years. Forcing you to work longer and harder for more money that is worth less. By using the "Trump Loophole", you can use a special retirement account to buy gold — and other precious metals — without taxes or penalties.

That's why we have released our Free Precious Metals Investment Guide that explains all the details

About enGene

enGene Holdings Inc., through its subsidiary enGene, Inc., operates as a clinical-stage biotechnology company that develops genetic medicines through the delivery of therapeutics to mucosal tissues and other organs. Its lead product candidate is EG-70 (detalimogene voraplasmid), which is a non-viral immunotherapy to treat non-muscle invasive bladder cancer patients with carcinoma-in-situ (Cis), who are unresponsive to treatment with Bacillus Calmette-Guérin. The company was founded in 2023 and is based in Saint-Laurent, Canada.

ENGNW Stock Price History

30 days | 90 days | 365 days | Advanced Chart

ENGNW Stock News Headlines

No headlines for this company have been tracked by MarketBeat.com

Receive ENGNW Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for enGene and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Sector: Medical
Industry: Biotechnology
Sub-Industry: N/A
Current Symbol: NASDAQ:ENGNW
CUSIP: N/A
CIK: 1980845
Web: www.engene.com
Phone: 514-332-4888
Fax: N/A
Employees: 31
Year Founded: N/A

Profitability

EPS (Most Recent Fiscal Year): N/A
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: N/A
Net Margins: N/A
Pretax Margin: N/A
Return on Equity: N/A
Return on Assets: N/A

Debt

Debt-to-Equity Ratio: N/A
Current Ratio: N/A
Quick Ratio: N/A

Sales & Book Value

Annual Sales: N/A
Price / Sales: N/A
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: N/A
Price / Book: N/A

Miscellaneous

Outstanding Shares: N/A
Free Float: N/A
Market Cap: N/A
Optionable: N/A
Beta: N/A

(Almost) Everything You Need To Know About The EV Market

Click the link below and we'll send you MarketBeat's guide to investing in electric vehicle technologies (EV) and which EV stocks show the most promise.

Get This Free Report

Key Executives

Mr. Jason D. Hanson Esq. (Age 55)
J.D., CEO & Director
Comp: $656.58k
Dr. Alex Nichols Ph.D. (Age 38)
President & COO
Comp: $504.44k
Dr. James C. Sullivan M.Sc. (Age 45)
Ph.D., Chief Scientific Officer
Comp: $524.29k
Dr. Anthony T. Cheung Ph.D. (Age 52)
Co-Founder & CTO
Comp: $341.75k
Mr. John C. Brown D.Sc.
FRSC, Ph.D., Co-Founder and Member of Scientific Advisory Board
Mr. David Ryan Daws (Age 50)
CFO & Head of Business Development
Mr. Lee G. Giguere (Age 43)
Chief Legal Officer & Corporate Secretary
Ms. Sharon Tan
VP of Project Management & Head of Program Management
Dr. Richard P. Bryce MBChB (Age 67)
MFPM, MRCGP, Chief Medical Officer
Dr. Raj Pruthi M.D.
Senior VP of Urologic Oncology & Clinical Development

Key Competitors

View All Competitors

ENGNW Stock Analysis - Frequently Asked Questions

How have ENGNW shares performed in 2024?: enGene's stock was trading at $0.85 at the beginning of the year. Since then, ENGNW stock has increased by 384.7% and is now trading at $4.12.
View the best growth stocks for 2024 here.
Are investors shorting enGene?: enGene saw a drop in short interest during the month of April. As of April 15th, there was short interest totaling 1,700 shares, a drop of 76.4% from the March 31st total of 7,200 shares. Based on an average daily trading volume, of 40,600 shares, the short-interest ratio is presently 0.0 days.
View enGene's Short Interest.
Is enGene a good dividend stock?: enGene (NASDAQ:ENGNW) pays an annual dividend of $1.58 per share and currently has a dividend yield of 0.00%.
How do I buy shares of enGene?: Shares of ENGNW stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:ENGNW) was last updated on 5/4/2024 by MarketBeat.com Staff

From Our Partners

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial